



4th Dresden International Symposium on Therapeutic Apheresis

1st Congress of the European
Group – International
Society for Apheresis

March 17 – 19, 2016 • Dresden, Germany

Alle Vorträge simultan in deutscher Sprache.

Thursday

MARCH 17,
2016

12:00-13:00 Industry PRE-Symposium by Aegerion
Pharmaceuticals GmbH

13:15-14:15 Opening session

13:15-13:30 **Welcome**

B. Hohenstein, Dresden (GER), S. Bornstein, Dresden (GER)

13:30-14:15 **History of lipidology and lipoprotein apheresis**

U. Julius, Dresden (GER)

14:15-14:30 Coffee break

HALL 3

14:30-16:30 Lp(a) in focus

Lp(a) lowering strategies – pathophysiology, methodological and therapeutic considerations

G. Kostner, Graz (AUT)

5-years results of the Pro(a)-Life study

R. Klingel, Cologne (GER)

Current insights into the German Lipoprotein Apheresis Registry and the German Apheresis Standard

V. Schettler, Goettingen (GER)

The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): results of a randomised controlled trial

T. Khan, London (UK)

Selected from abstracts

N.N.

MultiSELECT: A European multicenter study on the effect of lipoprotein(a) elimination by apheresis on cardiovascular outcomes

B. Hohenstein, Dresden (GER)

HALL 5

14:30-16:30 Future perspectives of lipoprotein apheresis

Lipoprotein apheresis in PAOD and Lp(a)-hyperlipoproteinemia: final results of a prospective single center study

K. Enke-Melzer, Berlin (GER)

The position of lipoprotein apheresis in the future: the perspective from preventive cardiology

E. Windler, Hamburg (GER)

Cascade screening for familial hypercholesterolemia: practical consequences

J. Roeters van Lennep, Rotterdam (NL)

Is there evidence for systematic screening programs in dyslipidemia?

W. Ramlow, Rostock (GER)

Challenges of nursing in apheresis units

tba.

Introduction of an international, European registry for lipid disorders

C. Peter, Rostock (GER)

16:30-17:00

Coffee break

HALL 3

17:00-19:00

Lipid disorders and PCSK9 inhibitors

Pharmacological insights into PCSK9 inhibition

A. El-Armouche, Dresden (GER)

Relevance of PCSK9 inhibitors for Lp(a) lowering

S. Tsimikas, San Diego (USA)

The efficacy of PCSK9 inhibitors: results from recent trials

I. Gouni-Berthold, Cologne (GER)

The ESCAPE trial – rationale, design and methods

P. Moriarty, Kansas City (USA)

PCSK9 inhibitors: Ready for routine prescription?

H. Berthold, Bielefeld (GER)

Selected from abstracts

HALL 5

17:00-19:00

Current aspects of lipidology and lipoprotein apheresis

Pleiotropic effects of double filtration plasmapheresis in the prevention of in-stent restenosis in patients with stable coronary artery disease

V. Tishko, St. Petersburg (RUS)

Plasmafiltration for the controlled removal of liposome therapeutics

M. Bláha, Prague (CZ)

Can imaging techniques reliably indicate the progression of coronary disease in high-risk patients?

R. Strasser, Dresden (GER)

Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis

V. Bláha, Prague (CZ)

LDL apheresis and coronary circulation.

T. Sampietro, Pisa (IT)

Selected from abstracts

19:00

Welcome reception at the Congress Center (Exhibition hall)



Friday

MARCH 18,
2016

HALL 3

08:30-10:00

New therapeutic areas

Is there a rationale for lipoprotein apheresis in patients with nephrotic syndrome?

M. Schiffer, Hanover (GER)

CRP elimination – The future therapy for acute myocardial infarction?

A. Sheriff, Hennigsdorf (GER)

Selection of preeclamptic women for sFLT1 elimination – whom should we treat?

R. Lachmann, Dresden (GER)

Evidence and strategies to use apheresis in pre-eclampsia

C. Kurschat, Cologne (GER)

HALL 5

08:30-10:00

Challenges and networks in apheresis

Indications and current situation of apheresis in Japan

Y. Endo, Shiga (JP)

The European Group of the International Society for Apheresis – scope and aims

J. Ringel, Potsdam (GER)

The Mighty-Medic network

U. Julius, Dresden (GER)

Perspectives for a lipidological competence network

F. Heigl, Kempten (GER)

10:00-10:15

Coffee break

HALL 3

10:15-11:45

Plenary session

Lp(a) antisense – Therapeutic perspective at the horizon?

S. Tsimikas, San Diego (USA)

The US guidelines for the treatment of dyslipidemia

C. Stefanutti, Rome (IT)

11:45-12:00

Coffee break

12:00-13:00

Industry symposium by Fresenius Medical Care Deutschland GmbH

13:00-14:00

Lunch break

14:00-15:30

Immunoabsorption – new insights

Modulation of the complement system with immunoabsorption – a major advantage?

G. Boehmig, Vienna (AUT)

Cell-based extracorporeal sepsis therapy

S. Mitzner, Rostock (GER)

Immunoabsorption for autoimmune encephalitis
N. Melzer, Muenster (GER)

Could immunoabsorption be a primary choice in acute multiple sclerosis?
T. Ziemssen, Dresden (GER)

16:00-17:30

Immunoabsorption – current aspects

Long-term immunoabsorption for lupus nephritis – new aspects justifying the extracorporeal approach?
K. Derfler, Vienna (AUT)

The role of immunoabsorption for pemphigus treatment
C. Guenther, Dresden (GER)

IgE elimination in atopic dermatitis – Whom, when and how?
E. von Stebut-Borschitz, Mainz (GER)

Effects of cryoprecipitation with active coal plasma adsorption and double filtration plasmapheresis for the treatment of myasthenia gravis
S. Bardakov, St. Petersburg (RUS), A. Sokolov, St. Petersburg (RUS)

HALL 5



Lipidologische Fortbildung der DGFF e. V. und der D•A•CH Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e. V. (Teilnahme kostenfrei)

14:00-15:30

Kaskaden-Screening für familiäre Hypercholesterolämie: Was wird erwartet?
W. Maerz, Mannheim (GER)

Möglichkeiten des Vorgehens bei Statintoleranz
S. Fischer, Dresden (GER)

Rolle der Lipoprotein-Apherese bei Patienten mit erhöhten Lipoprotein(a)-Spiegeln
U. Julius, Dresden (GER)

Kasuistiken von Patienten mit massiv erhöhten Lipoprotein(a)-Spiegeln
U. Schatz, Dresden (GER), S. Tselmin, Dresden (GER)

15:30-16:00

Coffee break

16:00-17:30

Genetische Analyse des Statin-Metabolismus: praktische Erfahrungen
S. Woehl, Ansbach, (GER)

Therapie der Hypertriglyzeridämie: Was gibt es Neues?
H.-U. Kloer, Gießen (GER)

Zielwerte für Lipide unter Berücksichtigung der neuen Therapieoptionen – was ist evidenzbasiert?
E. Windler, Hamburg (GER)

19:00

Gala dinner

Saturday

MARCH 19,
2016

HALL 3

09:00-10:30

Apheresis in nephrology and intensive care medicine

Extracorporeal treatment in antineutrophil cytoplasmic antibody-associated vasculitis

W. Szpirt, Copenhagen (DEN)

Immunoadsorption and hemodialysis as a tandem procedure

L. Rostaing, Toulouse (FRA)

Therapy of thrombotic microangiopathies – when do we need plasma exchange?

J. Kielstein, Braunschweig (GER)

A new adsorber to treat sepsis

S. Pokrovsky, Moscow (RUS)

HALL 5

09:00-10:30

HDL, triglycerides and apheresis

Inflammatory and apoE4-bound HDL pre and post apheresis

P. Moriarty, Kansas City (USA)

The role of HDL in patients with chronic kidney disease

C. Kopecky, Vienna (AUT)

Plasmapheresis in hypertriglyceridemia with acute pancreatitis – is there enough evidence?

H.-U. Kloer, Gießen (GER)

Lp(a) as a target for therapeutic apheresis

M. Ezhov, Moscow (RUS)

SEMINAR ROOM 5

09:00-10:30

Pflegesymposium (deutsch)

Das Leben über die Krankheit heben. Implementierung des Pflegemodells von Mieke Grypdonck in der Immunapherese

S. Ruppert, Vienna (AUT)

Ein Weiterbildungskonzept für die Apherese

K. Johné, Dresden (GER)

Experience as a nurse at the apheresis centre at the Harefield Hospital

A. Pottle, London (UK)

10:30-10:45

Coffee break

HALL 3

10:45-12:15

New drugs in lipidology

Experience with lipoprotein lipase gene therapy in familial hyperchylomicronemia

U. Kassner, Berlin (GER)

The role of antisense oligonucleotide therapy against apolipoprotein CIII in hypertriglyceridemia

I. Gouni-Berthold, Cologne (GER)

Experience with MTP inhibitor in homozygous familial hypercholesterolemia

K.-P. Mellwig, Bad Oeynhausen (GER)

Selected from abstracts

HALL 5

10:45-12:15

Cytapheresis and other target-oriented techniques

Recent advances in cell separation and harvesting techniques

K. Hoelig, Dresden (GER)

Novel concepts in extracorporeal photopheresis

H. Hackstein, Gießen (GER)

Efficacy and biocompatibility of cytapheresis systems

G. Waitz, Rostock (GER)

TAO update - the extracorporeal treatment perspective revisited

P. Klein-Weigel, Berlin (GER)

SEMINAR ROOM 5

10:45-12:15

Pflegesymposium (deutsch)

Wie funktionieren die neuen Substanzen zur Therapie von Fettstoffwechselstörungen?

tba.

Probleme der Venenpunktion bei Apheresepatienten

O. Kehl, Gießen (GER)

„28-mal vorbereitet“: ABO-inkompatible Nierentransplantation

K. Pickl-Herk, Vienna (AUT)

Antikoagulation bei Lipidapherese - zwischen Nachblutung und Clotting

I. Schulz-Merkel, Kempten

12:15-12:30

Coffee break

HALL 3

12:30-13:00

Concluding plenary session

General Information

SYMPOSIUM VENUE

International Congress Center Dresden
Ostra-Ufer 2
01067 Dresden, Germany

SCIENTIFIC CHAIRS

Prof. Dr. Bernd Hohenstein
Prof. Dr. Ulrich Julius
Extracorporeal Treatment and Lipoprotein Apheresis Center
Department of Internal Medicine III
University Hospital Carl Gustav Carus at the
Technische Universität Dresden, Germany

SYMPOSIUM SECRETARIAT

K.I.T. Group GmbH Dresden
Münzgasse 2
01067 Dresden, Germany

Phone: +49 351 4842731
E-mail: info@apheresis2016.de
www.apheresis2016.de

CME CERTIFICATION

The symposium has been certified with a total of 15 CME credit points.

REGISTRATION FEES

	Standard registration fee (by March 5, 2016)	Late registration fee (from March 6, 2016)
Delegate	175,00 €	225,00 €
Student*	75,00 €	100,00 €
Nursing staff (symposium incl. nursing training on Saturday)	75,00 €	100,00 €
Nursing staff (nursing training on Saturday only)	15,00 €	20,00 €
Members of the organizing hospital		100,00 €
Day ticket		150,00 €
Lipidologische Fortbildung		kostenfrei
Gala dinner		50,00 €

* Proof required

Registration is possible via the online registration form which can be found on the symposium's website www.apheresis2016.de.